Skip to main content
Erschienen in: Digestive Diseases and Sciences 6/2012

01.06.2012 | Perspective

Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues

verfasst von: Jason E. Bonner, A. Sidney Barritt IV, Michael W. Fried, Donna M. Evon

Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

A new era has dawned in the treatment of chronic hepatitis C (HCV) virus with the use of direct-acting antiviral medications augmenting combination therapy. Unfortunately, the significant impact of improvements may not be realized if antiviral treatment is not expanded to include a larger proportion of patients, many of whom have coexisting mental health and/or substance abuse issues and have been historically deferred from treatment.

Methods

We reviewed the extent literature on HCV treatment for individuals with co-occurring mental health and/or substance abuse issues.

Results

A number of empirically-based arguments exist in favor of treating HCV-infected individuals with mental health and/or substance abuse issues within the context of multidisciplinary team approaches. Integrated, collaborative, or hybrid models of care are just a few examples of multidisciplinary approaches that can combine the care of HCV treating providers with mental health and/or addictions providers to safely and effectively treat these patients. Collectively, these arguments and the empirical evidence that supports them, provides a strong rationale for why expanding antiviral therapy to these patients is critical and timely.

Conclusions

A decade of evidence suggests that HCV-infected individuals with mental health and/or substance abuse issues can safely and effectively undergo antiviral treatment when delivered through multidisciplinary care settings. Multidisciplinary approaches that combine HCV treating providers with mental health, addictions, and other support systems can facilitate preparation and successful treatment of these patients on antiviral therapy.
Literatur
1.
Zurück zum Zitat Jacobsen IM, McHutchison JG, Dusheiko GM, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416. Jacobsen IM, McHutchison JG, Dusheiko GM, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
2.
Zurück zum Zitat Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–1024. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–1024.
3.
Zurück zum Zitat Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
4.
Zurück zum Zitat Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521.PubMedCrossRef Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521.PubMedCrossRef
5.
Zurück zum Zitat Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother. 2010;65:1327–1329.PubMedCrossRef Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother. 2010;65:1327–1329.PubMedCrossRef
6.
Zurück zum Zitat Deuffic-Burban S, Poynard T, Sulkowski MS, et al. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007;14:107–115.PubMedCrossRef Deuffic-Burban S, Poynard T, Sulkowski MS, et al. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007;14:107–115.PubMedCrossRef
7.
Zurück zum Zitat El-Serag HB, Talwalkar J, Kim WR. Efficacy, effectiveness, and comparative effectiveness in liver disease. Hepatology. 2010;52:403–407.PubMedCrossRef El-Serag HB, Talwalkar J, Kim WR. Efficacy, effectiveness, and comparative effectiveness in liver disease. Hepatology. 2010;52:403–407.PubMedCrossRef
8.
Zurück zum Zitat Evon DM, Verma A, Dougherty KA, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci. 2007;52:3251–3258.PubMedCrossRef Evon DM, Verma A, Dougherty KA, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci. 2007;52:3251–3258.PubMedCrossRef
9.
10.
Zurück zum Zitat Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777–782.PubMedCrossRef Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777–782.PubMedCrossRef
11.
Zurück zum Zitat Willenbring ML. Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS. 2005;19:S227–S237.PubMedCrossRef Willenbring ML. Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS. 2005;19:S227–S237.PubMedCrossRef
12.
Zurück zum Zitat Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101:2254–2262.PubMedCrossRef Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101:2254–2262.PubMedCrossRef
13.
Zurück zum Zitat Hill WD, Butt G, Alvarez M, et al. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol. 2008;22:27–32.PubMed Hill WD, Butt G, Alvarez M, et al. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol. 2008;22:27–32.PubMed
14.
Zurück zum Zitat Zaller N, Gillani FS, Rich JD. A model of integrated primary care for HIV-positive patients with underlying substance use and mental illness. AIDS Care. 2007;19:1128–1133.PubMedCrossRef Zaller N, Gillani FS, Rich JD. A model of integrated primary care for HIV-positive patients with underlying substance use and mental illness. AIDS Care. 2007;19:1128–1133.PubMedCrossRef
15.
Zurück zum Zitat Arora S, Kalishman S, Thornton K, et al. Expanding access to hepatitis C virus treatment-Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology. 2010;52:1124–1133.PubMedCrossRef Arora S, Kalishman S, Thornton K, et al. Expanding access to hepatitis C virus treatment-Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology. 2010;52:1124–1133.PubMedCrossRef
16.
Zurück zum Zitat Fireman M, Indest DW, Blackwell A, et al. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis. 2005;40:S286–S291.PubMedCrossRef Fireman M, Indest DW, Blackwell A, et al. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis. 2005;40:S286–S291.PubMedCrossRef
17.
Zurück zum Zitat Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374.PubMedCrossRef Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374.PubMedCrossRef
19.
Zurück zum Zitat Gilfillan RJ, Tomcavage J, Rosenthal MB, et al. Value and the medical home: effects of transformed primary care. Am J Manag Care. 2010;16:607–614.PubMed Gilfillan RJ, Tomcavage J, Rosenthal MB, et al. Value and the medical home: effects of transformed primary care. Am J Manag Care. 2010;16:607–614.PubMed
20.
Zurück zum Zitat Goldberg RW. Supported medical care: a multi-faceted approach to helping HIV/hepatitis C virus co-infected adults with serious mental illness. AIDS. 2005;19:S215–S220.PubMedCrossRef Goldberg RW. Supported medical care: a multi-faceted approach to helping HIV/hepatitis C virus co-infected adults with serious mental illness. AIDS. 2005;19:S215–S220.PubMedCrossRef
21.
Zurück zum Zitat Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010;22:270–277.PubMedCrossRef Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010;22:270–277.PubMedCrossRef
22.
Zurück zum Zitat Sylvestre DL, Loftis JM, Hauser P, et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health. 2004;81:719–734.PubMedCrossRef Sylvestre DL, Loftis JM, Hauser P, et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health. 2004;81:719–734.PubMedCrossRef
24.
Zurück zum Zitat Bellentani S, Dalle GR, Suppini A, et al. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 2008;47:746–754.PubMedCrossRef Bellentani S, Dalle GR, Suppini A, et al. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 2008;47:746–754.PubMedCrossRef
25.
Zurück zum Zitat Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129.PubMedCrossRef Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129.PubMedCrossRef
26.
Zurück zum Zitat Pattullo V, Fernandes GS, Sockalingam S, et al. A 24-week dietary and physical activity intervention leads to sustained improvements in body mass index and insulin resistance in the obese with insulin resistant chronic hepatitis C. J Gastroenterol Hepatol. 2010;25:A120–A136. Pattullo V, Fernandes GS, Sockalingam S, et al. A 24-week dietary and physical activity intervention leads to sustained improvements in body mass index and insulin resistance in the obese with insulin resistant chronic hepatitis C. J Gastroenterol Hepatol. 2010;25:A120–A136.
27.
Zurück zum Zitat Lackner JM, Jaccard J, Krasner SS, et al. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol. 2008;6:899–906.PubMedCrossRef Lackner JM, Jaccard J, Krasner SS, et al. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol. 2008;6:899–906.PubMedCrossRef
28.
Zurück zum Zitat Lackner JM, Jaccard J, Krasner SS, et al. How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial. Gastroenterology. 2007;133:433–444.PubMedCrossRef Lackner JM, Jaccard J, Krasner SS, et al. How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial. Gastroenterology. 2007;133:433–444.PubMedCrossRef
29.
Zurück zum Zitat Blanchard EB, Lackner JM, Sanders K, et al. A controlled evaluation of group cognitive therapy in the treatment of irritable bowel syndrome. Behav Res Ther. 2007;45:633–648.PubMedCrossRef Blanchard EB, Lackner JM, Sanders K, et al. A controlled evaluation of group cognitive therapy in the treatment of irritable bowel syndrome. Behav Res Ther. 2007;45:633–648.PubMedCrossRef
30.
Zurück zum Zitat Evon DM, Simpson K, Kixmiller S, et al. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol. 2011;106:1777–1786.PubMedCrossRef Evon DM, Simpson K, Kixmiller S, et al. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol. 2011;106:1777–1786.PubMedCrossRef
31.
Zurück zum Zitat Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol. 2002;34:268–271.PubMedCrossRef Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol. 2002;34:268–271.PubMedCrossRef
32.
Zurück zum Zitat Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288–292.PubMed Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288–292.PubMed
33.
Zurück zum Zitat Butt AA, Wagener M, Shakil AO, et al. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat. 2005;12:81–85.PubMedCrossRef Butt AA, Wagener M, Shakil AO, et al. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat. 2005;12:81–85.PubMedCrossRef
34.
Zurück zum Zitat Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction. 2004;99:1167–1175.PubMedCrossRef Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction. 2004;99:1167–1175.PubMedCrossRef
35.
Zurück zum Zitat Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443–451.PubMedCrossRef Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443–451.PubMedCrossRef
36.
Zurück zum Zitat Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005;42:793–798.PubMedCrossRef Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005;42:793–798.PubMedCrossRef
37.
Zurück zum Zitat Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology. 2007;46:991–998.PubMedCrossRef Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology. 2007;46:991–998.PubMedCrossRef
38.
Zurück zum Zitat Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy. 2007;18:437–443.PubMedCrossRef Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy. 2007;18:437–443.PubMedCrossRef
39.
Zurück zum Zitat Sylvestre DL, Litwin AH, Clements BJ, et al. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat. 2005;29:159–165.PubMedCrossRef Sylvestre DL, Litwin AH, Clements BJ, et al. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat. 2005;29:159–165.PubMedCrossRef
40.
Zurück zum Zitat Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007;19:741–747.PubMedCrossRef Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007;19:741–747.PubMedCrossRef
41.
Zurück zum Zitat Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis. 2005;40:S325–S329.PubMedCrossRef Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis. 2005;40:S325–S329.PubMedCrossRef
42.
Zurück zum Zitat Freedman K, Nathanson J. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders. Expert Rev Anti Infect Ther. 2009;7:363–376.PubMedCrossRef Freedman K, Nathanson J. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders. Expert Rev Anti Infect Ther. 2009;7:363–376.PubMedCrossRef
43.
Zurück zum Zitat Zanini B, Covolo L, Donato F, et al. Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies. Clin Ther. 2010;32:2139–2159.PubMedCrossRef Zanini B, Covolo L, Donato F, et al. Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies. Clin Ther. 2010;32:2139–2159.PubMedCrossRef
44.
Zurück zum Zitat Bruggmann P, Dampz M, Gerlach T, et al. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend. 2010;110:167–171.PubMedCrossRef Bruggmann P, Dampz M, Gerlach T, et al. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend. 2010;110:167–171.PubMedCrossRef
45.
Zurück zum Zitat Bruggmann P, Falcato L, Dober S, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat. 2008;15:747–752.PubMedCrossRef Bruggmann P, Falcato L, Dober S, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat. 2008;15:747–752.PubMedCrossRef
46.
Zurück zum Zitat Volk ML, Tocco R, Saini S, et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750–1755.PubMedCrossRef Volk ML, Tocco R, Saini S, et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750–1755.PubMedCrossRef
47.
Zurück zum Zitat Lopez-Navas A, Rios A, Riquelme A, et al. Psychological characteristics of patients on the liver transplantation waiting list with depressive symptoms. Transplant Proc. 2011;43:158–160.PubMedCrossRef Lopez-Navas A, Rios A, Riquelme A, et al. Psychological characteristics of patients on the liver transplantation waiting list with depressive symptoms. Transplant Proc. 2011;43:158–160.PubMedCrossRef
48.
Zurück zum Zitat DiMartini A, Dew MA, Javed L, et al. Pretransplant psychiatric and medical comorbidity of alcoholic liver disease patients who received liver transplant. Psychosomatics. 2004;45:517–523.PubMedCrossRef DiMartini A, Dew MA, Javed L, et al. Pretransplant psychiatric and medical comorbidity of alcoholic liver disease patients who received liver transplant. Psychosomatics. 2004;45:517–523.PubMedCrossRef
49.
Zurück zum Zitat Rocca P, Cocuzza E, Rasetti R, et al. Predictors of psychiatric disorders in liver transplantation candidates: logistic regression models. Liver Transpl. 2003;9:721–726.PubMedCrossRef Rocca P, Cocuzza E, Rasetti R, et al. Predictors of psychiatric disorders in liver transplantation candidates: logistic regression models. Liver Transpl. 2003;9:721–726.PubMedCrossRef
50.
Zurück zum Zitat Butt AA, McGinnis KA, Skanderson M, et al. Hepatitis C treatment completion rates in routine clinical care. Liver Int. 2010;30:240–250.PubMedCrossRef Butt AA, McGinnis KA, Skanderson M, et al. Hepatitis C treatment completion rates in routine clinical care. Liver Int. 2010;30:240–250.PubMedCrossRef
51.
Zurück zum Zitat Zacks S, Beavers K, Theodore D, et al. Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol. 2006;40:220–224.PubMedCrossRef Zacks S, Beavers K, Theodore D, et al. Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol. 2006;40:220–224.PubMedCrossRef
52.
Zurück zum Zitat Zickmund S, Ho EY, Masuda M, et al. “They Treated Me Like a Leper”: stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003;18:835–844.PubMedCrossRef Zickmund S, Ho EY, Masuda M, et al. “They Treated Me Like a Leper”: stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003;18:835–844.PubMedCrossRef
Metadaten
Titel
Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues
verfasst von
Jason E. Bonner
A. Sidney Barritt IV
Michael W. Fried
Donna M. Evon
Publikationsdatum
01.06.2012
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 6/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2141-4

Weitere Artikel der Ausgabe 6/2012

Digestive Diseases and Sciences 6/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.